When is a biopsy-proven diagnosis necessary before stereotactic ablative radiotherapy for lung cancer? A decision analysis

Chest

Volumn 146, Issue 4, 2014, Pages 1021-1028

  Louie, Alexander V ^a,b,c   Senan, Suresh ^a   Patel, Pretesh ^d   Ferket, Bart S ^c,e   Lagerwaard, Frank J ^a   Rodrigues, George B ^b   Salama, Joseph K ^d   Kelsey, Christopher ^d   Palma, David A ^b   Hunink, Myriam G ^c,e  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DECISION TREE; FALSE NEGATIVE RESULT; HIDDEN MARKOV MODEL; LUNG CANCER; LUNG NODULE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; STEREOTACTIC ABLATIVE RADIOTHERAPY; STEREOTACTIC TREATMENT; TRANSTHORACIC BIOPSY; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; DECISION SUPPORT SYSTEM; HUMAN; LUNG NEOPLASMS; PROCEDURES; RADIOSURGERY; SOLITARY PULMONARY NODULE; TREATMENT OUTCOME;

BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; DECISION SUPPORT TECHNIQUES; HUMANS; LUNG NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOSURGERY; SENSITIVITY AND SPECIFICITY; SOLITARY PULMONARY NODULE; TREATMENT OUTCOME;

EID: 84907937831     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-2924     Document Type: Article

References (47)

1. Cykert S, Dilworth-Anderson P, Monroe MH, et al. Factors associated with decisions to undergo surgery among patients with newly diagnosed early-stage lung cancer. JAMA. 2010; 303 (23): 2368 - 2376.
2. Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 suppl):e278S-e313S.
3. Donington J, Ferguson M, Mazzone P, et al; Thoracic Oncology Network of American College of Chest Physicians; Workforce on Evidence-Based Surgery of Society of Thoracic Surgeons. American College of Chest Physicians and Society of Thoracic Surgeons consensus statement for evaluation and management for high-risk patients with stage I non-small cell lung cancer. Chest. 2012; 142 (6): 1620 - 1635.
4. Simone CB II, Wildt B, Haas AR, Pope G, Rengan R, Hahn SM. Stereotactic body radiation therapy for lung cancer. Chest. 2013; 143 (6): 1784 - 1790.
5. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010; 303 (11): 1070 - 1076.
6. Haasbeek CJ, Palma D, Visser O, Lagerwaard FJ, Slotman B, Senan S. Early-stage lung cancer in elderly patients: A population-based study of changes in treatment patterns and survival in the Netherlands. Ann Oncol. 2012; 23 (10): 2743 - 2747.
7. Gould MK, Donington J, Lynch WR, et al. Evaluation of individuals with pulmonary nodules: When is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 suppl):e93S-e120S.
8. Hiraki T, Mimura H, Gobara H, et al. CT fluoroscopy-guided biopsy of 1, 000 pulmonary lesions performed with 20-gauge coaxial cutting needles: diagnostic yield and risk factors for diagnostic failure. Chest. 2009; 136 (6): 1612 - 1617.
9. Guckenberger M, Allgäuer M, Appold S, et al. Safety and efficacy of stereotactic body radiotherapy for stage 1 non-small-cell lung cancer in routine clinical practice: A patterns-of-care and outcome analysis. J Thorac Oncol. 2013; 8 (8): 1050 - 1058.
10. Grills IS, Hope AJ, Guckenberger M, et al. A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy. J Thorac Oncol. 2012; 7 (9): 1382 - 1393.
11. Onishi H, Yoshiyuki S, Yasuo M, et al. Japanese multi-institutional study of stereotactic body radiation therapy for more than 2000 patients with stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013; 87 (suppl 2): S9-S10.
12. Baumann P, Nyman J, Hoyer M, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-smallcell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol. 2009; 27 (20): 3290 - 3296.
13. Van steenkiste J, De Ruysscher D, Eberhardt WE, et al; ESMO Guidelines Working Group. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24 (suppl 6): vi89 - vi98.
14. Herder GJ, van Tinteren H, Golding RP, et al. Clinical prediction model to characterize pulmonary nodules: validation and added value of 18 F-fluorodeoxyglucose positron emission tomography. Chest. 2005; 128 (4): 2490 - 2496.
15. Verstegen NE, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S. Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: com parison with a contemporaneous cohort with pathologically proven disease. Radiother Oncol. 2011; 101 (2): 250 - 254.
16. Gould MK, Ananth L, Barnett PG, Veterans Affairs SCSG; Veterans Affairs SNAP Cooperative Study Group. A clinical model to estimate the pretest probability of lung cancer in patients with solitary pulmonary nodules. Chest. 2007; 131 (2): 383 - 388.
17. Harkenrider MM, Bertke MH, Dunlap NE. Stereotactic body radiation therapy for unbiopsied early-stage lung cancer: A multi-institutional analysis. Am J Clin Oncol. 2014; 37 (4): 337 - 342.
18. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008; 26 (28): 4617 - 4625.
19. van Klaveren RJ, Oudkerk M, Prokop M, et al. Management of lung nodules detected by volume CT scanning. N Engl J Med. 2009; 361 (23): 2221 - 2229.
20. Arias E, Curtin LR, Wei R, Anderson RN. United States life tables, 2008. Natl Vital Stat Rep. 2012; 61 (3): 1 - 64.
21. Shavelle RM, Paculdo DR, Strauss DJ, Kush SJ. Smoking habit and mortality: A meta-analysis. J Insur Med. 2008; 40 (3-4): 170 - 178.
22. Wiener RS, Schwartz LM, Woloshin S, Welch HG. Population-based risk for complications after transthoracic needle lung biopsy of a pulmonary nodule: An analysis of discharge records. Ann Intern Med. 2011; 155 (3): 137 - 144.
23. Grutters JP, Kessels AG, Pijls-Johannesma M, De Ruysscher D, Joore MA, Lambin P. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: A metaanalysis. Radiother Oncol. 2010; 95 (1): 32 - 40.
24. Shah A, Hahn SM, Stetson RL, Friedberg JS, Pechet TT, Sher DJ. Cost-effectiveness of stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. Cancer. 2013; 119 (17): 3123 - 3132.
25. Longworth L, Rowen D. Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. Value Health. 2013; 16 (1): 202 - 210.
26. Lagerwaard FJ, Aaronson NK, Gundy CM, Haasbeek CJ, Slotman BJ, Senan S. Patient-reported quality of life after stereotactic ablative radiotherapy for early-stage lung cancer. J Thorac Oncol. 2012; 7 (7): 1148 - 1154.
27. Jang RW, Isogai PK, Mittmann N, et al. Derivation of utility values from European Organization for Research and Treatment of Cancer Quality of Life-Core 30 questionnaire values in lung cancer. J Thorac Oncol. 2010; 5 (12): 1953 - 1957.
28. Sturza J. A review and meta-analysis of utility values for lung cancer. Med Decis Making. 2010; 30 (6): 685 - 693.
29. Doyle S, Lloyd A, Walker M. Health state utility scores in advanced nonsmall cell lung cancer. Lung Cancer. 2008; 62 (3): 374 - 380.
30. Gould MK, Sanders GD, Barnett PG, et al. Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules. Ann Intern Med. 2003; 138 (9): 724 - 735.
31. Fryback DG, Lawrence WF Jr. Dollars may not buy as many QALYs as we think: A problem with defining qualityof- life adjustments. Med Decis Making. 1997; 17 (3): 276 - 284.
32. Louie AV, Rodrigues G, Hannouf M, et al. With holding stereotactic radiotherapy in elderly patients with stage I non-small cell lung cancer and co-existing COPD is not justified: outcomes of a Markov model analysis. Radiother Oncol. 2011; 99 (2): 161 - 165.
33. Raz DJ, Zell JA, Ou SH, Gandara DR, Anton-Culver H, Jablons DM. Natural history of stage I non-small cell lung cancer: Implications for early detection. Chest. 2007; 132 (1): 193 - 199.
34. National Comprehensive Cancer Network. NCCN guidelines for nonsmall cell lung cancer (V.3. 2014). National Comprehensive Cancer Network website. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp. Accessed March 21, 2014.
35. Cronin P, Dwamena BA, Kelly AM, Carlos RC. Solitary pulmonary nodules: Meta-analytic comparison of cross-sectional imaging modalities for diagnosis of malignancy. Radiology. 2008; 246 (3): 772 - 782.
36. Menn P, Leidl R, Holle R. A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease. Pharmacoeconomics. 2012; 30 (9): 825 - 840.
37. Cerfolio RJ, Bryant AS. Survival of patients with true pathologic stage I nonsmall cell lung cancer. Ann Thorac Surg. 2009;88(3):917-922.
38. Ost DE, Gould MK. Decision making in patients with pulmonary nodules. Am J Respir Crit Care Med. 2012; 185 (4): 363 - 372.
39. Senan S, Paul MA, Lagerwaard FJ. Treatment of early-stage lung cancer detected by screening: surgery or stereotactic ablative radiotherapy? Lancet Oncol. 2013; 14 (7): e270 - e274.
40. Field JK, Smith RA, Aberle DR, et al; IASLC CT Screening Workshop 2011 Participants. International Association for the Study of Lung Cancer Computed Tomography Screening Workshop 2011 report. J Thorac Oncol. 2012; 7 (1): 10 - 19.
41. Almeida FA, Casal RF, Jimenez CA, et al. Quality gaps and comparative effectiveness in lung cancer staging: The impact of test sequencing on outcomes. Chest. 2013; 144 (6): 1776 - 1782.
42. Deppen SA, Phillips S, McPheeters M, et al. Benign disease prevalence after surgical lung resection varies geographically in the US Medicare population, implications for lung cancer screening. In: Proceedings of the 104ThAnnual Meeting of the American Association for Cancer Research; April 6-10, 2013; Washington, DC. Abstract 3628.
43. Detterbeck FC, Gibson CJ. Turning gray: The natural history of lung cancer over time. J Thorac Oncol. 2008; 3 (7): 781 - 792.
44. Mehta HJ, Ravenel JG, Shaft man SR, et al. The utility of nodule volume in the context of malignancy prediction for small pulmonary nodules. Chest. 2014; 145 (3): 464 - 472.
45. McWilliams A, Tammemagi MC, Mayo JR, et al. Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med. 2013; 369 (10): 910 - 919.
46. Balekian AA, Silvestri GA, Simkovich SM, et al. Accuracy of clinicians and models for estimating the probability that a pulmonary nodule is malignant. Ann Am Thorac Soc. 2013; 10 (6): 629 - 635.
47. Crott R, Versteegh M, Uyl-de-Groot C. An assessment of the external validity of mapping QLQ-C30 to EQ-5D preferences. Q ual Life Res. 2013; 22 (5): 1045 - 1054.